Roussel Eduard, Capitanio Umberto, Kutikov Alexander, Oosterwijk Egbert, Pedrosa Ivan, Rowe Steven P, Gorin Michael A
Department of Urology, University Hospitals Leuven, Leuven, Belgium.
Department of Urology, University Vita-Salute, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eur Urol. 2022 May;81(5):476-488. doi: 10.1016/j.eururo.2022.01.040. Epub 2022 Feb 22.
The incidental detection of localized renal masses has been rising steadily, but a significant proportion of these tumors are benign or indolent and, in most cases, do not require treatment. At the present time, a majority of patients with an incidentally detected renal tumor undergo treatment for the presumption of cancer, leading to a significant number of unnecessary surgical interventions that can result in complications including loss of renal function. Thus, there exists a clinical need for improved tools to aid in the pretreatment characterization of renal tumors to inform patient management.
To systematically review the evidence on noninvasive, imaging-based tools for solid renal mass characterization.
The MEDLINE database was systematically searched for relevant studies on novel imaging techniques and interpretative tools for the characterization of solid renal masses, published in the past 10 yr.
Over the past decade, several novel imaging tools have offered promise for the improved characterization of indeterminate renal masses. Technologies of particular note include multiparametric magnetic resonance imaging of the kidney, molecular imaging with targeted radiopharmaceutical agents, and use of radiomics as well as artificial intelligence to enhance the interpretation of imaging studies. Among these, Tc-sestamibi single photon emission computed tomography/computed tomography (CT) for the identification of benign renal oncocytomas and hybrid oncocytic chromophobe tumors, and positron emission tomography/CT imaging with radiolabeled girentuximab for the identification of clear cell renal cell carcinoma, are likely to be closest to implementation in clinical practice.
A number of novel imaging tools stand poised to aid in the noninvasive characterization of indeterminate renal masses. In the future, these tools may aid in patient management by providing a comprehensive virtual biopsy, complete with information on tumor histology, underlying molecular abnormalities, and ultimately disease prognosis.
Not all renal tumors require treatment, as a significant proportion are either benign or have limited metastatic potential. Several innovative imaging tools have shown promise for their ability to improve the characterization of renal tumors and provide guidance in terms of patient management.
偶然发现的局限性肾肿块数量一直在稳步上升,但这些肿瘤中有很大一部分是良性或惰性的,在大多数情况下不需要治疗。目前,大多数偶然发现肾肿瘤的患者因被假定为癌症而接受治疗,导致大量不必要的手术干预,可能引发包括肾功能丧失在内的并发症。因此,临床上需要改进工具来辅助肾肿瘤的治疗前特征描述,以指导患者管理。
系统回顾基于成像的非侵入性工具用于实性肾肿块特征描述的证据。
系统检索MEDLINE数据库,查找过去10年发表的关于用于实性肾肿块特征描述的新型成像技术和解释工具的相关研究。
在过去十年中,几种新型成像工具为更好地描述不确定的肾肿块带来了希望。特别值得注意的技术包括肾脏多参数磁共振成像、靶向放射性药物的分子成像,以及使用放射组学和人工智能来增强成像研究的解读。其中,用于识别良性肾嗜酸细胞瘤和混合性嗜酸细胞嫌色细胞瘤的锝- sestamibi单光子发射计算机断层扫描/计算机断层扫描(CT),以及用于识别透明细胞肾细胞癌的放射性标记吉伦妥昔单抗正电子发射断层扫描/CT成像,可能最接近在临床实践中应用。
一些新型成像工具有望辅助对不确定的肾肿块进行非侵入性特征描述。未来,这些工具可能通过提供全面的虚拟活检来帮助患者管理,包括肿瘤组织学、潜在分子异常以及最终疾病预后等信息。
并非所有肾肿瘤都需要治疗,因为很大一部分要么是良性的要么转移潜力有限。几种创新成像工具已显示出有望改善肾肿瘤的特征描述并在患者管理方面提供指导。